Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy

This study tests whether adding dapagliflozin — a diabetes drug that also has heart and kidney benefits — to standard pre-surgery chemotherapy (neoadjuvant therapy) for certain breast cancers is safe and changes helpful biological markers. **You may be eligible if...** - You are a woman over 18 with newly diagnosed invasive breast cancer (clinical stage I-III) - Your breast cancer is HER2-negative (either hormone receptor-positive or triple-negative) - Your treatment plan includes pre-surgery chemotherapy **You may NOT be eligible if...** - Your breast cancer is HER2-positive - You are not scheduled for pre-surgery chemotherapy - You have certain health conditions that make it unsafe to take dapagliflozin Talk to your doctor to see if this trial is right for you.